AXSOME THERAPEUT. DL-0001 WKN: A2AA7B ISIN: US05464T1043 Kürzel: AXSM Forum: Aktien Thema: Hauptdiskussion
156,13
EUR
-0,05 % -0,08
22:18:43 Uhr,
L&S Exchange
Kommentare 3.473
Tycoon5c6995b9d084b,
Montag 11:57 Uhr
0
Eine der besten Bio buden
S
Slinvest,
9. Apr 19:14 Uhr
0
Die Aktie macht doch einfach nur Spaß. Bestes Pferd im Stall!
W
Wizardry2,
2. Apr 2:32 Uhr
0
https://finance.yahoo.com/sectors/healthcare/articles/axsome-therapeutics-acquires-selective-pde10a-110000091.html
Quan,
16. Mär 14:32 Uhr
0
Still geworden hier
W
Wizardry2,
15.01.2026 14:37 Uhr
0
https://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-initiates-forward-phase-3-trial-axs-14
W
Wizardry2,
31.12.2025 17:20 Uhr
0
😁
FCING01,
31.12.2025 15:53 Uhr
0
meinen Glückwunsch an alle investiert.
🥂😉👍🏻
W
Wizardry2,
31.12.2025 13:25 Uhr
0
https://stocktwits.com/news-articles/equity/markets/axsome-advances-toward-fda-filing-for-drug-to-treat-narcolepsy/cL7B4KPREzL
J
JoeLeTrump,
31.12.2025 13:07 Uhr
0
👀
J
JoeLeTrump,
31.12.2025 13:07 Uhr
0
Axsome Therapeutics (NASDAQ: AXSM) received formal FDA pre-NDA meeting minutes supporting an NDA submission for AXS-12 (reboxetine) to treat cataplexy in narcolepsy. The FDA agreed the company’s regulatory data package would be sufficient for an NDA filing. Axsome anticipates completing the NDA submission in January 2026, with acceptance subject to the FDA’s review of the complete filing.
AXS-12 clinical work includes three controlled efficacy trials and a completed long-term safety trial. AXS-12 holds Orphan Drug Designation, which may provide seven years of U.S. market exclusivity and potential user-fee waiver if approved.
J
JoeLeTrump,
31.12.2025 13:06 Uhr
0
Axsome Therapeutics (NASDAQ: AXSM) announced the FDA has accepted and granted Priority Review to its supplemental NDA for AXS-05 for treatment of Alzheimer’s disease agitation, with a PDUFA target action date of April 30, 2026.
The filing follows a comprehensive clinical program including four randomized, double-blind, controlled Phase 3 trials and a long-term safety trial. The FDA previously granted Breakthrough Therapy designation for AXS-05 in June 2020. Company commentary cites that up to 76% of people with Alzheimer’s experience agitation and that approved treatments are scarce.
W
Wizardry2,
06.11.2025 14:59 Uhr
0
https://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-acquires-subtype-selective-gaba-receptor
W
Wizardry2,
03.11.2025 14:15 Uhr
0
https://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-reports-third-quarter-2025-financial-results
W
Wizardry2,
02.10.2025 11:16 Uhr
1
https://www.forbes.com/sites/amyfeldman/2025/10/01/this-haiti-born-doctor-built-a-6-billion-business-developing-drugs-for-depression-and-alzheimers/
B
Bigge,
04.08.2025 15:57 Uhr
0
Das nervt heute Morgen 5 % und nu 4% runter
X
XXIO,
24.07.2025 17:16 Uhr
0
Bin jetzt bei 90 auch zum x-ten Mal eingestiegen
Meistdiskutiert
|
|
Thema | ||
|---|---|---|---|
| 1 | Hims & Hers Health Registered (A) Hauptdiskussion | +8,67 % | |
| 2 | Strategy B | +4,06 % | |
| 3 | NETFLIX Hauptdiskussion | -8,90 % | |
| 4 | Diginex | +0,74 % | |
| 5 | für alle, die es ehrlich meinen beim Traden. | ||
| 6 | Nio für normale Kommunikation | +7,06 % | |
| 7 | DAX Hauptdiskussion | +0,09 % | |
| 8 | Beyond Meat Hauptdiskussion | +6,51 % | |
| 9 | ITM POWER Hauptdiskussion | -2,78 % | |
| 10 | Critical Infrastructure Technologies Hauptdiskussion | -1,02 % | Alle Diskussionen |
Aktien
|
|
Thema | ||
|---|---|---|---|
| 1 | Hims & Hers Health Registered (A) Hauptdiskussion | +6,94 % | |
| 2 | Strategy B | +4,37 % | |
| 3 | NETFLIX Hauptdiskussion | -8,74 % | |
| 4 | Diginex | -1,72 % | |
| 5 | Nio für normale Kommunikation | +7,06 % | |
| 6 | Beyond Meat Hauptdiskussion | +5,95 % | |
| 7 | ITM POWER Hauptdiskussion | -2,41 % | |
| 8 | Critical Infrastructure Technologies Hauptdiskussion | -3,05 % | |
| 9 | PILBARA MINERALS Hauptdiskussion | +6,31 % | |
| 10 | HEIDELBERGER DRUCKMASCHINEN Hauptdiskussion | -9,18 % | Alle Diskussionen |